慢性原发免疫性血小板减少症药物治疗研究现状

Research Status of Medications for Chronic Primary Immune Thrombocytopenic

原发免疫性血小板减少症(primary immune thrombocytopenic,ITP)是临床上常见的自身免疫性疾病,初始治疗多以皮质类固醇、免疫抑制剂为主,但不少慢性患者疗效欠佳。近年来,酪氨酸激酶抑制剂、新生儿Fc受体(FcRn)抑制剂及PRTX-100等药物在慢性ITP患者治疗中展现了一定的疗效。本文就新型药物在慢性ITP中的临床应用和进展进行综述。

Primary immune thrombocytopenic(ITP)is a common autoimmune disease in clinical.Initial therapy is mostly based on corticosteroid and immunosuppressant.However,many chronic patients have poor efficacy.In recent years,the drugs such as tyrosine kinase inhibitors,FcRn inhibitiors and PRTX-100 have shown some efficacy in patients with chronic ITP.This article summarizes the clinical application and progress of new-type drugs in chronic ITP.